21/01/2026 – AB Science today announced that the Japanese Patent Office has formally granted a patent for methods of treating progressive multiple sclerosis (MS) with its lead compound masitinib Download PDF Post navigationPreviousPrevious post:AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemiaNextNext post:AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancerRelated PostsAB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS24 February 2026FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®9 February 2026AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer29 January 2026AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia7 January 2026
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS24 February 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer29 January 2026
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia7 January 2026